MPS Pharmaa Ltd (ADLB)

Currency in INR
2.35
0.00(0.00%)
Closed·

ADLB Financial Summary

Key Ratios

P/E Ratio-5
Price/Book4.05
Debt / Equity690.1%
Return on Equity-58.89%
Dividend Yield0.00%
EBITDA-7.17M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/03
2017
31/03
2018
31/03
2019
31/03
2020
31/03
2021
31/03
2022
31/03
2023
31/03
2024
31/03
2025
31/03
* In Millions of INR (except for per share items)

Earnings

Latest Release
May 28, 2025
EPS / Forecast
-0.24 / --
Revenue / Forecast
437.00K / --
EPS Revisions
Last 90 days

FAQ

What were MPS Pharmaa's earnings for the latest quarter?

The MPS Pharmaa EPS (TTM) is -0.47. MPS Pharmaa reported sales of 0.44, net income of -4.54, and EPS of -0.24 for the latest quarter.

What was MPS Pharmaa's net income for the latest quarter?

MPS Pharmaa's net income for the latest quarter was -4.54.

How did MPS Pharmaa's performance compare year-over-year in the latest quarter?

The company's revenue moved from 0.04 in the previous quarter to 0.44 in the latest quarter, and net income moved from -4.44 to -4.54 compared to the previous quarter.

What is MPS Pharmaa's net profit margin on a TTM basis?

MPS Pharmaa's trailing twelve months (TTM) net profit margin is -1,882.39%.

How does MPS Pharmaa's debt to equity ratio compare to industry standards?

MPS Pharmaa's total debt-to-equity ratio is 690.10%.

What is MPS Pharmaa's return on investment on a TTM basis?

MPS Pharmaa's trailing twelve months (TTM) return on investment (ROI) is -58.89%.

Did MPS Pharmaa gain or lose cash last quarter?

In the latest quarter, MPS Pharmaa's net change in cash was -0.02 million.

What were MPS Pharmaa's total assets and liabilities in the latest quarter?

As of the latest quarter, MPS Pharmaa reported total assets of 93.32 million and total liabilities of 80.67 million.

How has MPS Pharmaa's total revenue grown this year?

MPS Pharmaa's total revenue was 0.04 in the previous quarter and 0.44 in the latest quarter.

What is MPS Pharmaa's gross margin on a TTM basis?

MPS Pharmaa's trailing twelve months (TTM) gross margin is 100.00%.

What was MPS Pharmaa's revenue per share for the latest quarter?

MPS Pharmaa's revenue per share for the latest quarter was 302.29.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.